RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 27 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 27

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  3. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  4. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  5. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  6. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  7. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  8. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  9. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  10. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  11. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  12. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  13. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  14. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  15. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  16. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  17. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
  18. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  19. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  20. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  21. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  22. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  23. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  24. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  25. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  26. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  27. Study siteWest China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07082686, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histopathologically confirmed MCL expressing Cyclin D1 and/or t (11;14) chromosomal translocation.Formalin-fixed paraffin-embedded (FFPE) tissues or sections for diagnosis must be provided. It is for the approval of pathological diagnosis by the central pathology laboratory.

    Inclusion criterion 2

  3. Prior use of BCL-2 inhibitors (e.g., venetoclax/ABT-199, etc.).

    Exclusion criterion 2

  4. ECOG performance status of 0-2 .

    Inclusion criterion 8

  5. At least one measurable lesion according to the Lugano 2014 criteria,.

    Inclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07082686, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • ≥ 18 years old.
  • Histopathologically confirmed MCL expressing Cyclin D1 and/or t (11;14) chromosomal translocation.Formalin-fixed paraffin-embedded (FFPE) tissues or sections for diagnosis must be provided. It is for the approval of pathological diagnosis by the central pathology laboratory.
  • The patient was diagnosed with relapsed or refractory mantle cell lymphoma, and the previous treatment needs to meet the following requirements:
  • Failure of at least one adequate prior line of anti-CD20-containing therapy;
  • Failure of at least one adequate prior line of BTK inhibitor (BTKi)-containing therapy.
  • Failure of the last line of therapy.
  • At least one measurable lesion according to the Lugano 2014 criteria,.
  • ECOG performance status of 0-2 .

Exclusion Criteria

  • Current or prior history of central nervous system (CNS) lymphoma.
  • Prior use of BCL-2 inhibitors (e.g., venetoclax/ABT-199, etc.).
  • Autologous stem cell transplantation or cellular therapy within 3 months prior to the first dose of ICP-248.
  • Prior allogeneic hematopoietic stem cell transplantation.

Quoted from ClinicalTrials.gov, NCT07082686, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07082686, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07082686